Rani (RANI)
Develops RaniPill capsules for oral delivery of biologics and drugs.
Something off on this page? Send us feedback.
Develops RaniPill capsules for oral delivery of biologics and drugs, alongside internal and partner programs. The clinical-stage business has one operating segment, with RaniPill GO and HC configurations and contract revenue rather than a mature product portfolio.
Develops the RaniPill, a swallowable robotic capsule intended to deliver biologics and drugs through the intestinal wall. The platform is designed as an oral alternative to injectable delivery and has two configurations: RaniPill GO for microtablets and RaniPill HC for liquid payloads.
Its internal pipeline includes RT-114, an oral GLP-1/GLP-2 dual agonist, and RT-116, an oral semaglutide program; RT-117 pairs RaniPill HC with a Chugai compound for hemophilia. The company reports one operating segment and contract revenue rather than a mature commercial product portfolio. Development depends on clinical progress and collaborations including ProGen and Chugai.
Company facts
Target rangeAs of Sep 21, 2026
Latest analyst notes
No analyst notes in the last 24 months.
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $53.4M · Total debt $3.5M · Total assets $60.8M · Shareholders' equity $39.2M
- Revenue
- $1.7M
- Operating income
- −$8.8M
- Net income
- −$7.4M
No dividends on record.
| Institutions | 32.76% | 45.66M shares | |
|---|---|---|---|
| 70 holders · as of Jun 30, 2026 | |||
| Insiders | 34.08% | 47.51M shares | |
| 6 holders · as of Jul 23, 2026 | |||
| Other | 33.16% | 46.22M shares | |
| remainder | |||
139.40M company shares as of Sep 22, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
Two share counts disagree (139.40M in the company's Sep 22, 2026 report, 65.32M elsewhere); stakes use the report.
This company has 2 share classes; every stake here is a share of the whole company.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
Mir A. ImranInsiderdirector, 10 percent owner | 19.42% | 2.12M A · 24.95M B | filed Jul 23, 2026 |
Srinivas AkkarajuInsider | 8.12% | 11.32M | filed May 28, 2026 |
Samsara Biocapital, LLCInstitution | 7.44% | 10.37M A | as of Jun 30, 2026 |
Invus Public Equities, L.P.Insider | 6.18% | 8.62M | filed Oct 23, 2025 |
Ra Capital Management, L.P.Institution | 6.10% | 8.50M A | as of Jun 30, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Jul 21, 2026 | Mir A. Imran | director, 10 percent owner: | +36,000 | $0.6900 |
| Dec 27, 2024 | Talat Imran | director, officer: Chief Executive Officer | −8,014 | $1.41 |
| Jul 17, 2026 | Talat Imran | director, officer: Chief Executive Officer | +35,000 | $0.7198 |
| Mar 27, 2026 | Alireza Javadi | officer: Chief Technical Officer | −386 | $0.7800 |
| Oct 23, 2025 | Mir A. Imran | director, 10 percent owner: | +4,166,668 | $0.5425 |
- Novo Nordisk (ADR)
Oral and injectable GLP-1 therapies in obesity
- Eli Lilly
Injectable incretin therapies in obesity
- Entera Bio
Oral peptide delivery and obesity programs
- Lexaria Bioscience
Oral GLP-1 formulation technology
- AbbVie
Injectable biologics versus oral delivery
- Johnson & Johnson
Injectable biologic therapies versus oral delivery
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Rani | $0.7857 | −0.47% | $51.6M | — | — | 10.6 | — |
| Novo Nordisk (ADR) | $39.58 | −0.57% | $176.83B | 9.9 | 16.3 | 3.5 | +1.3% |
| Eli Lilly | $1,172.61 | +0.66% | $1.10T | 39.1 | 28.7 | 13.8 | +47.7% |
| Entera Bio | $2.99 | +0.84% | $145.9M | — | — | — | — |
| Lexaria Bioscience | $3.43 | +0.15% | $5.7M | — | — | 29.2 | −88.5% |
| AbbVie | $265.82 | +0.51% | $467.37B | 74.5 | 17.5 | 7.3 | +10.2% |
| Johnson & Johnson | $269.34 | −0.05% | $649.40B | 31.2 | 22.7 | 6.6 | +6.6% |
| Median | 35.1 | 20.1 | 7.3 | +6.6% |